182 related articles for article (PubMed ID: 31915854)
1. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer.
Holmström MO; Cordua S; Skov V; Kjær L; Pallisgaard N; Ellervik C; Hasselbalch HC; Andersen MH
Cancer Immunol Immunother; 2020 Feb; 69(2):315-324. PubMed ID: 31915854
[TBL] [Abstract][Full Text] [Related]
2. High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.
Holmström MO; Ahmad SM; Klausen U; Bendtsen SK; Martinenaite E; Riley CH; Svane IM; Kjær L; Skov V; Ellervik C; Pallisgaard N; Hasselbalch HC; Andersen MH
Blood Cancer J; 2019 Jan; 9(2):8. PubMed ID: 30655510
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.
Cimen Bozkus C; Roudko V; Finnigan JP; Mascarenhas J; Hoffman R; Iancu-Rubin C; Bhardwaj N
Cancer Discov; 2019 Sep; 9(9):1192-1207. PubMed ID: 31266769
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With
Handlos Grauslund J; Holmström MO; Jørgensen NG; Klausen U; Weis-Banke SE; El Fassi D; Schöllkopf C; Clausen MB; Gjerdrum LMR; Breinholt MF; Kjeldsen JW; Hansen M; Koschmieder S; Chatain N; Novotny GW; Petersen J; Kjær L; Skov V; Met Ö; Svane IM; Hasselbalch HC; Andersen MH
Front Oncol; 2021; 11():637420. PubMed ID: 33718228
[TBL] [Abstract][Full Text] [Related]
5. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
6. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
Edahiro Y; Araki M; Komatsu N
Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
[TBL] [Abstract][Full Text] [Related]
7. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.
Holmström MO; Andersen M; Traynor S; Ahmad SM; Lisle TL; Handlos Grauslund J; Skov V; Kjær L; Ottesen JT; Gjerstorff MF; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1240678. PubMed ID: 37662956
[TBL] [Abstract][Full Text] [Related]
10. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
12. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
Merlinsky TR; Levine RL; Pronier E
Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
[TBL] [Abstract][Full Text] [Related]
13. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.
Holmström MO; Martinenaite E; Ahmad SM; Met Ö; Friese C; Kjær L; Riley CH; Thor Straten P; Svane IM; Hasselbalch HC; Andersen MH
Leukemia; 2018 Feb; 32(2):429-437. PubMed ID: 28676668
[TBL] [Abstract][Full Text] [Related]
14. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
Araki M; Komatsu N
Cancer Sci; 2017 Oct; 108(10):1907-1912. PubMed ID: 28741795
[TBL] [Abstract][Full Text] [Related]
15. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
16. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
[TBL] [Abstract][Full Text] [Related]
17. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
18. The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in
Pan Y; Wang X; Wen S; Liu X; Yang L; Luo J
Hematology; 2022 Dec; 27(1):902-908. PubMed ID: 36000955
[TBL] [Abstract][Full Text] [Related]
19. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations.
Takei H; Edahiro Y; Mano S; Masubuchi N; Mizukami Y; Imai M; Morishita S; Misawa K; Ochiai T; Tsuneda S; Endo H; Nakamura S; Eto K; Ohsaka A; Araki M; Komatsu N
Br J Haematol; 2018 Jun; 181(6):791-802. PubMed ID: 29741776
[TBL] [Abstract][Full Text] [Related]
20. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]